Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.
Entresto is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalisation. Entresto should be administered in combination
with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
II receptor blocker (ARB). Entresto should be initiated, and up-titration conducted, by
a physician experienced with the treatment of heart failure.